293 related articles for article (PubMed ID: 16707435)
1. Hypoxia increases androgen receptor activity in prostate cancer cells.
Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM
Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435
[TBL] [Abstract][Full Text] [Related]
2. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation.
Park SY; Yu X; Ip C; Mohler JL; Bogner PN; Park YM
Cancer Res; 2007 Oct; 67(19):9294-303. PubMed ID: 17909037
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
5. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
6. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
[TBL] [Abstract][Full Text] [Related]
8. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
[TBL] [Abstract][Full Text] [Related]
9. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells.
Horii K; Suzuki Y; Kondo Y; Akimoto M; Nishimura T; Yamabe Y; Sakaue M; Sano T; Kitagawa T; Himeno S; Imura N; Hara S
Mol Cancer Res; 2007 Apr; 5(4):383-91. PubMed ID: 17426252
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
12. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
Suzuki Y; Kondo Y; Hara S; Kimata R; Nishimura T
Int J Urol; 2010 Mar; 17(3):281-5. PubMed ID: 20409220
[TBL] [Abstract][Full Text] [Related]
13. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
Dai J; Shen R; Sumitomo M; Stahl R; Navarro D; Gershengorn MC; Nanus DM
Clin Cancer Res; 2002 Jul; 8(7):2399-405. PubMed ID: 12114445
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 in patients with prostate cancer.
Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
[TBL] [Abstract][Full Text] [Related]
16. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE
Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
18. Interrogating androgen receptor function in recurrent prostate cancer.
Zhang L; Johnson M; Le KH; Sato M; Ilagan R; Iyer M; Gambhir SS; Wu L; Carey M
Cancer Res; 2003 Aug; 63(15):4552-60. PubMed ID: 12907631
[TBL] [Abstract][Full Text] [Related]
19. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
20. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
Yuan H; Gong A; Young CY
Carcinogenesis; 2005 Apr; 26(4):793-801. PubMed ID: 15661808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
